Outsourcing

Pre-Interphex 2010 Product Releases.

To best carry out the vision of Hatch-Waxman, Congress must act now on biogenerics.

Contract manufacturers report improving business conditions, but will they continue?

Brief pharmaceutical news items for March 2010.

Analysis of the opportunities and challenges in the biosimilars market.

From last-minute product inserts to putting out fires, close calls are a common occurrence.

It's time to maintain a thorough traceable excipient trail.

If both sides of the aisle don't agree on even mild healthcare reform soon, the bill could die out.

The vice-president addresses shifts in process and more.

Pharmaceutical companies and their suppliers share approaches in risk mitigation in sourcing and ways to optimize the outsourced relationship.

The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.

The author examines the use and advantages of disposable technologies in the fill–finish of sterile pharmaceutical products and how these technologies can reduce costs and time in producing clinical-trial materials.

Merck To Eliminate 15,000 jobs; Tauzin Stepping Down At PhRMA; And More.

RUSNANO, a corporation established by the Russian government to foster the development of nanotechnology, launched a project last week to manufacture targeted-delivery nanodrugs to treat malignant neoplasms.

The Society for Chemical Manufacturers and Affiliates offered its support for a Senate proposal to extend to 2015 current chemical-security standards, the Chemical Facility Anti-Terrorism Standards, which are set to expire this year.

Abbott Completes Acquisition Of Solvay; Merck Names President of Consumer Healthcare; And More.

Margaret Hamburg, commissioner of the US Food and Drug Administration, unveiled a new program to improve the efficiency of import inspections.

VaxGen Shareholders Reject OXiGENE Merger; Roche Creates Research Hub In Singapore; And More.

Cephalon Buys Mepha; BASi's CEO Retires; and More.

Strategic rather than tactical considerations are driving biopharmaceutical outsourcing.

Sharing too much-or too little-information can have disastrous onsequences.

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

Regulators and industry move to require inspections of API manufacturing facilities.

When it comes to healthcare rform, we must not overlook investment in innovative technologies.

Leading experts share insight on the current and future direction of process analytical technology. This article contains bonus online material.